CdM | Oryzon Genomics has announced that the Mexican Patent Office has issued a decision to grant patent application MX/a/2021/011610, entitled ‘Combinations of iadademstat for cancer therapy’. The approved claims protect the use of iadademstat in combination with PD1 or PD-L1 inhibitors for the treatment of cancer, including small cell lung cancer (SCLC). Once formally granted, the patent is expected to provide protection until at least 2040, not including possible…

Link Securities | Oryzon Genomics (ORY) announced that the European Medicines Agency (EMA) has approved its Clinical Trial Authorisation (CTA) application to initiate a Phase II study with iadademstat in patients with essential thrombocythaemia (ET), thus expanding the clinical development of the drug beyond acute leukaemia to other haematological indications, according to the Bolsamanía website. The study, called IDEAL (Iadademstat treatment for Essential Thrombocythaemia), will be a multicentre, open-label, single-arm…

Link Securities | Oryzon Genomics (ORY) announced on Monday that it has received a Grant Decision from the Japanese Patent Office for its application JP2023-136283, entitled ‘Methods for treating behavioural disorders’, related to vafidemstat, its LSD1 inhibitor in clinical development for the treatment of psychiatric disorders, according to Bolsamania.com. The approved claims cover the use of vafidemstat for the treatment of aggression and social withdrawal, two symptoms associated with various…

ORYZON GENOMICS (ORY) announced on Monday that the Japan Patent Office has issued a Grant Decision for patent application JP2021-557187, entitled ‘Combinations of iadademstat for cancer therapy,’ strengthening the global protection of its iadademstat compound. Once the formal grant is issued, the company expects the patent to remain in force until at least 2040, excluding any possible extension of its term. With this decision, ORY has secured patent protection for…

Link Securities | Oryzon’s Extraordinary General Shareholders’ Meeting has approved, among other matters, a capital increase of up to €125 million, as reported by the company through the National Securities Market Commission (CNMV). Specifically, it has approved “a capital increase, through cash contributions and with the exclusion of pre-emptive subscription rights, in an effective amount of up to €125 million and delegation to the Board of Directors of the power…